Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peresolimab · 1 trial · 1 indication
PK: Cmax of Peresolimab
PK: AUC\[0-tlast\] of Peresolimab
PK: AUC(0-∞) of Peresolimab
| Arm | Type | Description |
|---|---|---|
| Peresolimab (Test 1) | EXPERIMENTAL | Peresolimab administered subcutaneously (SC). |
| Peresolimab (Test 2) | EXPERIMENTAL | Peresolimab administered SC. |
| Peresolimab (Test 3) | EXPERIMENTAL | Peresolimab administered SC. |
| Peresolimab (Reference) | EXPERIMENTAL | Peresolimab administered SC. |
| Name | Type | Description |
|---|---|---|
| Peresolimab | DRUG | Administered SC |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical history, physical examination, and other screening procedures * A minimum body weight of 45 kilograms and body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive, a...
Peresolimab is an investigational small molecule being studied in healthy participants. It is being evaluated in a clinical trial to assess the relative bioavailability of different Peresolimab formulations. The drug is not approved for any disease and is in early-stage clinical development.
Peresolimab is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research on this investigational small molecule drug.
Peresolimab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being studied in healthy volunteers to evaluate the bioavailability of its formulations.
Peresolimab has one completed Phase 1 clinical trial registered as NCT05959109. This study, titled "A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants," enrolled 57 healthy adults in the United States and evaluated the bioavailability of different drug formulations.
Yes, Peresolimab is also known as LY3462817. The clinical trial NCT05959109 references this alternative name in its title, confirming that both names refer to the same investigational drug being developed by Eli Lilly and Company.